Trans-NIH Recovery Act Research Support
Inactive
- Assistance listing
- 93.701
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- 7,907 $7,160,159,049 in federal obligations
Program facts
- Assistance types
-
- Project Grant
- Cooperative Agreement
- Eligible applicants
-
- U.S. Territories and possessions (includes institutions of higher education and hospitals)
- Beneficiaries
-
- Sponsored organization
- Public nonprofit institution/organization
- State
- Small business
- Profit organization
- Other private institution/organization
- Native American Organizations
- Private nonprofit institution/organization
- Quasi-public nonprofit organization
- U.S. Territories
- Federally Recognized Indian Tribal Governments
- Federal
- Local
- Other public institution/organization
- Specialized group (e.g. health professionals, students, veterans)
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The National Institutes of Health administered the Trans-NIH Recovery Act Research Support program (CFDA 93.701) to fund economic stimulus initiatives under the American Recovery and Reinvestment Act of 2009, with the most recent grant award dated September 30, 2010.
This program is no longer active. The portfolio closed with 7,907 total awards distributed over a concentrated period: 258 awards in 2006, 278 in 2007, 289 in 2008, then a sharp spike to 4,304 in 2009 and 1,131 in 2010, corresponding to the Recovery Act's implementation and wind-down. No grant awards have been disbursed since 2010. The source lists no currently open grant opportunities; the two opportunities in the recent-opportunities block are successor-in-interest and change-of-grantee-organization procedures (PA-18-589 and PA-18-590), not new solicitations for ARRA research funding.
Funded projects spanned the full spectrum of NIH research: basic biomedical science (genomic analysis of tuberculosis, epigenetic control of memory, bacterial symbionts as drug sources), clinical and translational research (infantile spasms treatment, comparative effectiveness of diabetic retinopathy detection, rituximab therapy for Type 1 diabetes), and health services research (decision support tools, behavioral economics interventions for cardiovascular disease prevention, palliative care research infrastructure). Awards also supported capacity-building in research methodology, workforce development for underrepresented groups in STEM, and institutional comparative effectiveness research programs.
The National Institutes of Health dominated funding, awarding 7,905 of 7,907 total awards worth $7.14 billion in federal obligations. One award of $17.7 million went through the National Institute of Allergy and Infectious Diseases, and one award of $3.4 million went through HHS outside the NIH structure. Project Grants comprised 98 percent of the portfolio (7,729 awards) with Cooperative Agreements at 2 percent (178 awards).
Combined federal obligations totaled $7.16 billion. Representative award magnitudes ranged from under $200,000 (intracranial magnetic stimulation research at $228,000) to over $12 million (new players in immune function at $12.58 million, behavioral economics for cardiovascular disease at $12.49 million). Median award magnitude based on the recent-awards sample fell in the $1.5 million to $3 million range.
Do not pursue this program. It was a time-limited ARRA vehicle that concluded in 2010 and has generated no new grant opportunities or awards in the subsequent sixteen years.
Objective and description
- Objective
To provide support for initiatives funded under The American Recovery and Reinvestment Act of 2009 (ARRA). These projects will provide economic stimulus to the nation while furthering the NIH mission to uncover new knowledge that will lead to better health for everyone.
Grant opportunities
| Opportunity | Status | Posted | Applications due |
|---|---|---|---|
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | Closed | ||
| Change of Grantee Organization (Type 7 Parent Clinical Trial Optional) | Closed |
Grant awards
Latest 10 of 7,907 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | University Of Washington | $163,437,896 | 2% |
| 2 | Regents Of The University Of Michigan | $142,026,125 | 2% |
| 3 | The Trustees Of The University Of Pennsylvania | $139,393,350 | 2% |
| 4 | The Johns Hopkins University | $124,494,507 | 2% |
| 5 | The Leland Stanford Junior University | $121,409,077 | 2% |
| 6 | Duke University | $119,314,370 | 2% |
| 7 | Yale Univ | $111,134,231 | 2% |
| 8 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $109,828,048 | 2% |
| 9 | Brigham & Womens Hospital Inc. | $101,600,101 | 1% |
| 10 | University Of California, LOS Angeles | $96,697,501 | 1% |
10 of 925 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2021 | -$7,245 |
| FY2020 | $7,245 |
| FY2013 | -$257,753 |
| FY2012 | $188,890 |
| FY2011 | -$3,767,948 |
| FY2010 | $3,868,266,737 |
| FY2009 | $4,307,028,009 |
Quick answers
What is Assistance Listing 93.701?
Assistance Listing 93.701 is Trans-NIH Recovery Act Research Support, a federal grant program run by National Institutes of Health (Department of Health and Human Services). It is inactive.
What is the CFDA number for Trans-NIH Recovery Act Research Support?
Its CFDA number is 93.701: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.701 awarded?
7,907 grant awards under 93.701 have obligated $7,160,159,049 in federal funds to 925 recipients.
Who receives the most funding from 93.701?
The recipients obligated the most under Trans-NIH Recovery Act Research Support are University Of Washington ($163,437,896), Regents Of The University Of Michigan ($142,026,125) and The Trustees Of The University Of Pennsylvania ($139,393,350).
Are there open grant opportunities under 93.701?
No opportunity listed under 93.701 is open now. The latest, Successor-in-Interest (Type 6 Parent Clinical Trial Optional), was posted on January 26, 2018.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program